HIV-Associated Lipodystrophy Treatment Market In-Depth Analysis with Booming Trends Supporting Growth Till 2026| Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc.

HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of lipodystrophy in people infected with HIV varies between 10% and 80%.

Major market players of HIV-associated lipodystrophy treatment market
Key players operating in global HIV-associated lipodystrophy treatment market include Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb.

Download the PDF brochure: www.coherentmarketinsights.com/insight/request-pdf/1269

According to an article published in Journal of AIDS & Clinical Research in 2014, prevalence of lipodystrophy in patients suffering from HIV varies significantly and was estimated between 32.4% and 88.6%. According to World Health Organization (WHO) in 2017, more than 35 million people are suffering from HIV worldwide and an estimated 1.0 million people died from HIV in 2016. Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy market as most (32.4-88.6%) of the people suffering from HIV also suffer from HIV-associated lipodystrophy.

Approval of novel drugs in key regions such as North America is expected to drive the growth of HIV-Associated Lipodystrophy Market. For instance, in 2014, Theratechnologies Inc. received approval from Health Canada for its EGRIFTA. It is a growth hormone-releasing factor (GRF) for the treatment of HIV-associated lipodystrophy. EGRIFTA had also received the U.S. Food and Drug Administration (FDA) approval in 2010. Such approval of new drugs in the key region is expected to drive growth of the HIV-associated lipodystrophy treatment market.

Global HIV-Associated Lipodystrophy Treatment Market Taxonomy
The global HIV-associated lipodystrophy treatment market is segmented on the basis of lipodystrophy type, therapeutic class, and distribution channel.

On the basis of lipodystrophy type, the global HIV-associated lipodystrophy treatment market is segmented into:
Lipoatrophy
Lipoaccumulation
On the basis of therapeutic class, the global HIV-associated lipodystrophy treatment market is segmented into:
Anabolism modulators
Growth hormones
On the basis of the distribution channel, the global HIV-associated lipodystrophy treatment market is segmented into:
Hospital pharmacies
Retail pharmacies

Request For A Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1269

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.